Community Intervention to Eliminate HCV Among People Who Use Drugs.

Launched by ANRS, EMERGING INFECTIOUS DISEASES · Mar 20, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on finding effective ways to screen and treat hepatitis C (HCV) among people who use drugs in several cities in France, including Paris, Lyon, Marseille, and Fort-de-France. The researchers want to see if their community-based approach can help identify more people with HCV and start their treatment right away. They will also look into the mental health and other health issues that might affect drug users, as well as understand the challenges some people face in receiving treatment for HCV. Additionally, they want to learn how participants feel about the referral process for mental health care, comparing those who get help at the research site versus those referred to local facilities.

To participate, you must be over 18 years old and actively using drugs, which includes having a positive urine test for certain substances. If you join the study, you'll be screened for hepatitis C and other health issues and receive treatment as needed. The researchers will also provide you with coupons to encourage your friends to get involved. This trial aims to improve care for people who use drugs and help eliminate hepatitis C in the community, so your participation could make a significant difference for many.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Age \> 18 years;
• * Person who uses drugs, defined as:
• • Reported psychoactive substance use and
• • Positive urine test for at least one of the following: heroin, amphetamines, cocaine, MDMA (methylenedioxymethamphetamine), ecstasy, or misused opioid medications (methadone, buprenorphine or opiates used for a reason other than its original prescription (effects seeking) or used in a way that does not comply with its marketing authorisation (injected, snorted, taken multiple times beyond the prescribed dosage)) ;
• • Informed and signed consent
• Exclusion criteria:
• • Inability to understand the study;
• • Being under guardianship, curatorship or mandate of future protection;
• • Person participating in another research study with an exclusion period still in progress at the time of pre-inclusion.